Results 1 to 10 of about 7,224 (167)

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate

AIDS Research and Therapy
Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil ...
Hamed Mirmoezzi, Hamid Emadi Koochak, Seyed Ali Dehghan Manshadi, Malihe Hasannezhad, SeyedAhmad SeyedAlinaghi, Kiavash Semnani, Ladan Abbasian, Sara Ghaderkhani   +7 more
doaj   +1 more source

Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis

Frontiers in Pharmacology
ObjectivesTo systematically evaluate the efficacy and safety of tenofovir and entecavir in chronic hepatitis B-related cirrhosis.MethodsA comprehensive search was conducted in databases including PubMed, Web of Science, Embase and Cochrane Library from ...
Lu Cao, Li Li, Lixing Yang, Nan Zhou, Yu Zhang   +4 more
doaj   +1 more source

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study

Journal of Clinical Virology Plus
Background: Tenofovir disoproxil fumarate (TDF) as first-line therapy for chronic HBV infection is related to nephrotoxicity. Tenofovir alafenamide fumarate (TAF) has been approved with a similar virological and serological response, but lower toxicity ...
Giacomo Stroffolini, Valentina Dodaro, Amedeo De Nicolò, Jessica Cusato, Giovanni Di Perri, Antonio D'Avolio, Lucio Boglione   +6 more
doaj   +1 more source

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy

Drug Design, Development and Therapy, 2017
Eiichi Ogawa,1 Norihiro Furusyo,1 Mindie H Nguyen2 1Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan; 2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto,
Ogawa E, Furusyo N, Nguyen MH
doaj  

Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase

Вопросы вирусологии
Introduction. The amino acid substitution A62V in reverse transcriptase was identified as a mutation correlated with virologic failure in patients on first-line therapy including tenofovir (TDF) and tenofovir alafenamide (TAF).
Ekaterina N. Ozhmegova, Anna I. Kuznetsova, Aleksey V. Lebedev, Anastasia A. Antonova, Kristina V. Kim, Yana M. Munchak, Alexander S. Tumanov, Elena V. Kazennova   +7 more
doaj   +1 more source

Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta‐Analysis

JGH Open
Background Hepatitis B virus (HBV) infection causes liver disease, including hepatocellular carcinoma. Controlling viral activity is crucial to reducing complications.
Muhammad Shahzil, Ammad Javaid Chaudhary, Talha Kashif, Ali Akram Qureshi, Anza Muhammad, Faiza Khan, Muhammad Saad Faisal, Muhammad Ali Khaqan, Hassam Ali, Yara Dababneh, Dilip Moonka   +10 more
doaj   +1 more source

The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan

MDM Policy & Practice
Background. Chronic hepatitis B (CHB) is a lifelong disease requiring long-term or indefinite therapy, resulting in substantial economic burden. Thus, careful consideration must be used in the selection of therapies. Aim.
Elise Chia-Hui Tan, Alon Yehoshua, Sushanth Jeyakumar, Pongo Peng, Amy Lin, Nathaniel J. Smith, Nandita Kachru   +6 more
doaj   +1 more source

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Health Science Reports
Background and Aims People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)‐associated negative metabolic consequences.
Ping‐Feng Wu, Hsi‐Hsun Lin, Hsin‐Pai Chen, Po‐Chieh Huang, Meng‐Yu Ke   +4 more
doaj   +1 more source

Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States

Infectious Diseases and Therapy
Introduction HIV/hepatitis B virus (HBV) coinfection elevates the risk of liver-related complications compared to HIV or HBV mono-infections. While some antiretroviral therapy (ART) regimens slow liver disease progression, the long-term effects of ...
Ching-Yi Chuo, Woodie Zachry, Melanie de Boer, Laura Telep, Li Tao   +4 more
doaj   +1 more source

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide

Journal of Antimicrobial Chemotherapy, 2019
Marta Boffito, Anton Pozniak, Charles Flexner   +2 more
exaly